ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharmaceuticals (ANIP) PT Raised to $73 at Raymond James
February 28, 2019 7:42 AM ESTRaymond James analyst Elliot Wilbur raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $73.00 (from $63.00) while maintaining a Strong Buy rating following another strong quarter.
Wilbur said they believe the outperformance in 4Q18 as well as solid initial 2019 guidance... More
ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
February 27, 2019 8:34 AM ESTANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.32, $0.08 better than the analyst estimate of $1.24. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $53.48 million.
For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46Adjusted non-GAAP EBITDA of $22.2 millionAdjusted non-GAAP diluted earnings per share of $1.32Arthur... More
